CJC-1295 Without DAC vs. CJC-1295 No DAC (Same Peptide)

The peptide research field has a branding problem. Two identical compounds. CJC-1295 without DAC and CJC-1295 no DAC. Circulate under different names across supplier catalogs, research protocols, and scientific literature. Vendors alternate between 'without' and 'no' as if they're distinct peptides. They're not. Both refer to the same 29-amino-acid sequence: Mod GRF (1-29), also called CJC-1295 in its unmodified form. The distinction isn't chemical. It's a naming artifact left over from early clinical development when researchers needed to differentiate the short-acting base peptide from the DAC-modified long-acting version.

Our team has supplied this peptide to research institutions for years, and we've seen the confusion firsthand. Laboratories order both 'without DAC' and 'no DAC' separately, assuming they're stocking two different compounds. They're not. The naming split exists because early adopters used inconsistent terminology, and the market never standardised. This article clarifies what CJC-1295 without DAC and CJC-1295 no DAC actually are, why the names diverged, and what researchers need to know before ordering.

Is CJC-1295 without DAC the same as CJC-1295 no DAC?

Yes, CJC-1295 without DAC and CJC-1295 no DAC are the exact same peptide. Both refer to Mod GRF (1-29), the unmodified 29-amino-acid growth hormone releasing hormone analog. The naming variance comes from vendor terminology inconsistency, not chemical difference. Both trigger pulsatile growth hormone release with a half-life of approximately 30 minutes, clearing rapidly from circulation unlike the DAC-modified version which extends half-life to six days.

The Naming Problem: Why Two Terms for One Peptide

Here's the root of the confusion: CJC-1295 was originally developed as a DAC-modified peptide. The Drug Affinity Complex (DAC) is a synthetic linker that binds to serum albumin, extending the peptide's half-life from under an hour to approximately six days. When researchers wanted the short-acting base peptide without that modification, they had to specify 'without DAC' or 'no DAC' to distinguish it from the default DAC-modified version. Both phrases mean the same thing. The absence of the half-life extending modification.

The peptide underneath, regardless of what you call it, is Mod GRF (1-29). A truncated analog of growth hormone releasing hormone (GHRH) with four amino acid substitutions that increase stability compared to native GHRH (1-29). Those substitutions occur at positions 2, 8, 15, and 27, replacing residues prone to enzymatic degradation. The result is a peptide that retains GHRH's receptor binding profile but resists breakdown long enough to be useful in controlled research settings. The DAC modification is an optional attachment. It's not part of the core peptide structure. When vendors list 'CJC-1295 without DAC' and 'CJC-1295 no DAC' as separate products, they're mislabeling. It's the same sequence, synthesised the same way, with identical biological activity.

CJC-1295 Without DAC vs With DAC: The Functional Distinction That Actually Matters

The only meaningful distinction in this category is not 'without' versus 'no'. It's whether or not the DAC modification is present. CJC-1295 with DAC (also called DAC:GRF) has a half-life of approximately five to seven days, allowing once- or twice-weekly dosing. CJC-1295 without DAC (Mod GRF 1-29) has a half-life of roughly 30 minutes, requiring dosing timed to coincide with natural growth hormone pulse windows. Typically before sleep or around resistance training sessions. The pharmacokinetic difference is substantial: the DAC version produces sustained elevation of baseline growth hormone levels, while the non-DAC version amplifies existing pulses without altering baseline.

This distinction matters in research contexts because the two peptides model different physiological scenarios. The DAC-modified version mimics continuous low-level GHRH stimulation. Similar to what would occur if the hypothalamus released GHRH steadily throughout the day. The non-DAC version mimics a single, sharp GHRH pulse. Matching the natural pattern where growth hormone is released in discrete bursts tied to circadian rhythm, sleep architecture, and metabolic state. Most researchers select the non-DAC version precisely because it preserves pulsatility, which is critical for downstream signaling pathways that depend on oscillating hormone levels rather than static elevation. Our experience at Real Peptides shows that laboratories studying circadian biology or metabolic pulsatility almost exclusively request the short-acting form.

Mod GRF (1-29): The Correct Scientific Designation

If you want to eliminate confusion entirely, use the peptide's formal designation: Mod GRF (1-29). This is the name that appears in peer-reviewed literature and avoids the DAC naming problem altogether. The 'Mod' indicates the four amino acid substitutions that differentiate it from native GHRH (1-29), and the '(1-29)' specifies the sequence length. Some suppliers list it as 'Modified GRF 1-29' or simply 'GRF (1-29) amide'. These are all referring to the same peptide. CJC-1295, when used without further specification, technically refers to the DAC-modified version because that was the original designation in early clinical trials. However, common usage has muddied this. Many vendors and research protocols now use 'CJC-1295' to mean the non-DAC version by default, which creates the opposite confusion.

The safest approach: verify the sequence. If the supplier provides the amino acid sequence or molecular weight, confirm it matches Mod GRF (1-29). Molecular weight approximately 3,367 Da for the free acid form, 3,366 Da for the amidated form. If they list 'CJC-1295 with DAC' or provide a molecular weight above 4,000 Da, that's the long-acting version with the albumin-binding modification. If they list 'CJC-1295 without DAC', 'CJC-1295 no DAC', 'Mod GRF (1-29)', or 'Modified GRF 1-29' with a molecular weight around 3,367 Da. Those are all the same short-acting peptide. We've seen research groups inadvertently order both terms from different suppliers, only to discover through HPLC analysis that they received identical peptides.

CJC-1295 Without DAC vs. CJC-1295 No DAC: Full Comparison

Every key attribute of CJC-1295 without DAC and CJC-1295 no DAC is identical because they are the same peptide. The comparison below clarifies what researchers should focus on when evaluating this compound.

What If: CJC-1295 Research Scenarios

What If I Already Ordered Both 'Without DAC' and 'No DAC' — Did I Waste Resources?

No, but you now have duplicate inventory. Run HPLC or mass spectrometry on both batches to confirm they're identical, then consolidate your stock under a single label to avoid future redundancy. Some laboratories keep both labels active for internal tracking purposes. As long as you know they're the same compound, there's no operational issue. The financial waste was in placing two separate orders for what should have been a single bulk purchase.

What If My Protocol Specifies 'CJC-1295' Without Further Clarification?

Assume the author means the non-DAC version unless the protocol explicitly mentions sustained or baseline growth hormone elevation. Most research protocols using 'CJC-1295' without qualification are referring to the short-acting Mod GRF (1-29) because that's the version used in pulsatile studies. If the protocol describes once-weekly dosing or refers to 'extended half-life', that's the DAC version. When in doubt, contact the protocol author or check the cited literature for molecular weight or sequence data.

What If I Need the Long-Acting Version — How Do I Ensure I Get CJC-1295 With DAC?

Request 'CJC-1295 with DAC' explicitly, and verify the molecular weight exceeds 4,000 Da due to the albumin-binding linker. Reputable suppliers like Real Peptides provide full characterisation data including mass spectrometry and HPLC purity reports. Review those documents before committing to a large order. If a vendor lists 'CJC-1295' generically without specifying DAC status, ask directly. The price difference is often substantial. DAC-modified peptides typically cost more due to the additional synthesis complexity.

The Unvarnished Truth About CJC-1295 Naming Conventions

Here's the honest answer: the peptide industry created this confusion and has done almost nothing to fix it. Vendors perpetuate the 'without DAC' versus 'no DAC' split because it allows them to list the same peptide twice in their catalog, giving the appearance of broader inventory. It's not malicious. It's lazy. The scientific community uses Mod GRF (1-29) consistently in peer-reviewed publications, but commercial suppliers cling to 'CJC-1295' branding because it's more recognizable to researchers who learned the terminology from older protocols. The result is a market where the same peptide appears under four or five different names depending on which supplier you're browsing.

If you're ordering from a supplier who can't confirm whether their 'CJC-1295 without DAC' is the same as their 'CJC-1295 no DAC', find a different supplier. Any vendor who understands peptide chemistry should be able to clarify this immediately. And if they can't, that's a red flag about their quality control processes. We've worked with laboratories who received three separate shipments labeled 'CJC-1295', 'CJC-1295 without DAC', and 'Mod GRF (1-29)' from the same vendor, only to discover through internal testing that all three were identical batches. That's not rigorous inventory management. It's repackaging the same compound under multiple SKUs to inflate product counts.

CJC-1295 without DAC and CJC-1295 no DAC aren't just similar. They're the exact same 29-amino-acid sequence. The distinction is purely semantic. If your research requires the short-acting GHRH analog, both terms will get you the correct peptide. If you need absolute clarity, order by the formal designation: Mod GRF (1-29). And if you're comparing suppliers, ask for molecular weight confirmation before purchasing. That single data point eliminates all naming ambiguity.

Frequently Asked Questions

"faqs": [ { "question": "Is CJC-1295 without DAC the same as CJC-1295 no DAC?", "answer": "Yes, CJC-1295 without DAC and CJC-1295 no DAC are identical. Both refer to Mod GRF (1-29), the short-acting GHRH analog with a 30-minute half-life. The naming variance is vendor terminology inconsistency, not chemical difference. If you're ordering either term from a reputable supplier, you're receiving the same peptide." }, { "question": "What is the difference between CJC-1295 with DAC and without DAC?", "answer": "CJC-1295 with DAC has a Drug Affinity Complex linker that extends half-life to approximately six days by binding to serum albumin, while CJC-1295 without DAC (Mod GRF 1-29) clears within 30 minutes. The DAC version produces sustained baseline GH elevation; the non-DAC version amplifies natural GH pulses without altering baseline. This is the only functional distinction that matters." }, { "question": "Why do suppliers list both 'without DAC' and 'no DAC' separately?", "answer": "Suppliers list both because early research protocols used inconsistent terminology, and vendors never standardised. Some laboratories search for 'without DAC', others for 'no DAC'. Listing both increases catalog visibility. It's not a chemical distinction. Reputable suppliers clarify that the two terms refer to the same peptide; less transparent vendors allow the confusion to persist." }, { "question": "What is the correct scientific name for CJC-1295 without DAC?", "answer": "The correct designation is Mod GRF (1-29) or Modified GRF 1-29, referring to a 29-amino-acid growth hormone releasing hormone analog with four stabilising substitutions at positions 2, 8, 15, and 27. This name appears in peer-reviewed literature and avoids all DAC-related naming confusion. If you order by this term, you eliminate ambiguity entirely." }, { "question": "How can I verify I received the correct peptide?", "answer": "Check the molecular weight on the supplier's Certificate of Analysis. Mod GRF (1-29) is approximately 3,367 Da (free acid) or 3,366 Da (amidated). If the molecular weight exceeds 4,000 Da, you received the DAC-modified version. HPLC purity and mass spectrometry data confirm sequence identity. Reputable suppliers provide this documentation with every batch." }, { "question": "Does CJC-1295 without DAC require different storage than the DAC version?", "answer": "No, both versions require identical storage: lyophilised powder at −20°C, reconstituted solution refrigerated at 2–8°C and used within 28 days. The DAC modification does not alter thermal stability or degradation kinetics in storage. Temperature excursions above 8°C denature both peptides equally, rendering them inactive." }, { "question": "Can I use CJC-1295 without DAC and no DAC interchangeably in the same protocol?", "answer": "Yes, because they are the same peptide. If your protocol calls for 'CJC-1295 without DAC' and you have 'CJC-1295 no DAC' in stock, proceed without modification. The biological activity, receptor binding, half-life, and dosing requirements are identical. Verify molecular weight if you're uncertain about batch identity." }, { "question": "Why does the peptide research community still use 'CJC-1295' instead of Mod GRF (1-29)?", "answer": "CJC-1295 was the original clinical trial designation, and many researchers learned the terminology from early protocols. The name persists despite being less precise than Mod GRF (1-29). Commercial suppliers perpetuate 'CJC-1295' branding because it's more recognizable, even though the scientific literature has largely shifted to the formal amino acid sequence designation." }, { "question": "What happens if I accidentally order the DAC version when I need the short-acting peptide?", "answer": "The DAC-modified version will not replicate the pulsatile growth hormone response pattern required for most short-acting protocols. It produces sustained baseline elevation instead of discrete pulses. Contact your supplier immediately to exchange or return the product. Reputable vendors accommodate this mistake because it's common due to naming confusion." }, { "question": "Where can I order high-purity CJC-1295 without DAC with full characterisation data?", "answer": "Real Peptides supplies Mod GRF (1-29) with complete mass spectrometry, HPLC purity analysis, and amino acid sequencing documentation. Every batch is synthesised in small runs to exact specifications, ensuring consistency across orders. You can explore our research peptide collection to compare options and review technical documentation before purchasing." } ] }

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286